Vol 54, No 6 (2023)
Clinical vignette
Published online: 2023-11-28
Acquired hemophilia A as a rare complication in the course of myeloproliferative syndrome: diagnostic dilemmas in medical practice
DOI: 10.5603/ahp.96446
Acta Haematol Pol 2023;54(6):417-419.
Abstract
Not available
Keywords: acquired hemophiliamyeloproliferative neoplasmsbleeding
References
- Windyga J, Baran B, Odnoczko E, et al. Guidelines for the management of acquired hemophilia A in elderly patients. J Transf Med. 2021; 14(4): 137–155.
- Hoppe A, Rupa-Matysek J, Gil L. Clinical challenge of managing patients with multiple myeloma and acquired hemophilia A with risk of both thrombosis and bleeding: a narrative review. Acta Haematol Pol. 2022; 53(5): 303–315.
- Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020; 105(7): 1791–1801.
- Tiede A, Wahler S. The rising incidence of acquired haemophilia A in Germany. Haemophilia. 2021; 27(4): e466–e468.
- Góra-Tybor J. Therapy of Philadelphia-negative myeloproliferative neoplasms in the blast phase. Acta Haematol Pol. 2021; 52(4): 278–283.
- Prejzner W, Mital A, Bieniaszewska M, et al. Clinical characteristics of essential thrombocythemia patients depend on the mutation status. Acta Haematol Pol. 2020; 51(4): 230–235.
- McMullin MF, Anderson LA. Aetiology of myeloproliferative neoplasms. Cancers. 2020; 12(7): 1810.
- Borro M, Tassara R, Paris L, et al. Acquired hemophilia a treated with recombinant porcine factor VIII: case report and literature review on its efficacy. Hematol Rep. 2023; 15(1): 17–22.
- Biss T, Crossman L, Neilly I, et al. An acquired factor VIII inhibitor in association with a myeloproliferative/myelodysplastic disorder presenting with severe subcutaneous haemorrhage. Haemophilia. 2003; 9(5): 638–641.
- Vener C, Artoni A, Boschetti C, et al. An acquired factor VIII inhibitor in a myeloproliferative neoplasm presenting with severe retroperitoneal hemorrhage. Leuk Lymphoma. 2012; 53(11): 2296–2298.